Drug Profile


Alternative Names: Albumin-binding somatropin - Novo Nordisk; Long-acting growth hormone - Novo Nordisk; Long-acting somatropin - Novo Nordisk; NN 8640; NNC-0195-0092

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Somatotropin deficiency

Most Recent Events

  • 03 Mar 2017 Phase-III clinical trials in Somatotropin deficiency (Treatment-experienced, Combination therapy) in Japan (SC) (NCT03075644)
  • 01 Jan 2017 Novo Nordisk completes a phase I trial in Somatotropin deficiency (In volunteers) in Netherlands (SC) (NCT02962440)
  • 30 Nov 2016 Phase-I clinical trials in Somatotropin deficiency (In volunteers) in Netherlands (SC) (NCT02962440)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top